SavedAdd your journal

Journals / Klinik Psikofarmakoloji Bülteni / 2016 / Cilt: 26 - Sayı: 3

Attention deficit hyperactivity disorder treatment practice in Turkey

Özgür ÖNER
Fatma ISLİ
Hasan KARADAG
Akif AKBULAT
Ali Boray BASCİ
Mesil AKSOY
Cem SECKİN
Ali ALKAN
Hakan TURKCAPAR
Pages
265–272
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Age, gender and drug of choice were important factors associated with treatment adherence.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To determine the factors associated with type of ADHD prescription and re-admission of the cases to the outpatient clinics between January-July 2013.
📊
Key Findings & Data:Method: The Ministry of Health prescription database, which included prescriber, region, age and gender data and contained almost 20% of IMS data.
💡
Conclusion & Impact:Age, gender and drug of choice were important factors associated with treatment adherence.
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To determine the factors associated with type of ADHD prescription and re-admission of the cases to the outpatient clinics between January-July 2013. Method: The Ministry of Health prescription database, which included prescriber, region, age and gender data and contained almost 20% of IMS data. Results: A total of 73,189 prescription were prescribed to a total of 41,341 (30,014 males; 72.7%) patients. 38645 (93.5%) of the patients were between 6 and 18 years of age. The most frequently prescribed drug was OROS methylphenidate (MPH, 59.7%) followed by IR MPH, atomoxetine and combination of drugs. There were several regional differences in prescription practice. Treatment choice changed significantly with age and gender. Rate of repeated prescription was highest among 6-18 year-old male subjects receiving combination treatment. Conclusions: ADHD treatment choice seemed to be heavily influenced by official regulations. Age, gender and drug of choice were important factors associated with treatment adherence.

🔖

Cite This Article

ÖNER, Ö., ISLİ, F., KARADAG, H., AKBULAT, A., BASCİ, A. B., AKSOY, M., SECKİN, C., ALKAN, A., TURKCAPAR, H. (2022). Attention deficit hyperactivity disorder treatment practice in Turkey. Klinik Psikofarmakoloji Bülteni, Cilt: 26 - Sayı: 3, 265–272. https://ajindex.com/articles/573910

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Oner O, Yilmaz ES, Karadag H, Vural M, Vural EH, Akbulat A, Gursoz H, Turkcapar H, Kerman S. ADHD Medication Trends in Turkey: 2009-2013. J Atten Disord. 2014, [Epub ahead of print] [CrossRef]2. Hodgkins P, Sasané R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther 2011
  2. 33(2):188-203. [CrossRef]3. Trece-o C, Martín Arias LH, Sáinz M, Salado I, García Ortega P, Velasco V, et al. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiol Drug Saf 2012
  3. 21(4):435-41. [CrossRef]4. Prosser B, Reid R. Changes in use of psychostimulant medication for ADHD in South Australia (1990-2006). Aust N Z J Psychiatry 2009
  4. 43(4):340-7. [CrossRef]. Steinhausen HC, Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand 2014
  5. 129(3):221-31. [CrossRef]6. Zuvekas SH, Vitiello B. Stimulant medication use in children: a 12-year perspective. Am J Psychiatry 2012
  6. 169(2):160-6. [CrossRef]7. Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT. Psychotropic medication in children: a study from the Netherlands. Pediatrics 2001
  7. 108(2):E25. [CrossRef]8. Knellwolf AL, Deligne J, Chiarotti F, Auleley GR, Palmieri S, Boisgard CB, et al. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 2008
  8. 64(3):311-7. [CrossRef]9. Trip AM, Visser ST, Kalverdijk LJ, de Jong-van den Berg LT. Large increase of the use of psycho-stimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 2009
  9. 67(4):466-8. [CrossRef]10. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008
  10. 47(1):21-31. [CrossRef]11. Weyandt LL, Marraccini ME, Gudmundsdottir BG, Zavras BM, Turcotte KD, Munro BA, et al. Misuse of prescription stimulants among college students: a review of the literature and implications for morphological and cognitive effects on brain functioning. Exp Clin Psychopharmacol 2013
  11. 21(5):385-407. [CrossRef]12. Angold A, Erkanli A, Egger HL, Costello EJ. Stimulant treatment for children: a community perspective.